TABLE 1.
Patient demographics and baseline characteristics of Japanese patients who entered the reSURFACE 1 long‐term extension study
| Patient characteristics | TIL 100 mg (n = 54) | TIL 200 mg (n = 66) | Total (N = 120) |
|---|---|---|---|
| Gender male, n (%) | 40 (74.1) | 53 (80.3) | 93 (77.5) |
| Age (years) | 47.1 ± 12.4 | 49.1 ± 12.1 | 48.2 ± 12.2 |
| Weight (kg) | 67.9 ± 13.0 | 72.1 ± 15.1 | 70.2 ± 14.3 |
| BMI (kg/m2) | 24.6 ± 4.0 | 25.4 ± 4.6 | 25.0 ± 4.4 |
| Baseline disease characteristics | |||
| BSA (%) | 42.1 ± 18.6 | 46.5 ± 23.1 | 44.5 ± 21.2 |
| PASI score | 25.3 ± 8.8 | 27.7 ± 13.1 | 26.6 ± 11.4 |
| PGA score, n (%) | |||
| 3 | 24 (44.4) | 33 (50.0) | 57 (47.5) |
| 4 | 28 (51.9) | 29 (43.9) | 57 (47.5) |
| 5 | 2 (3.7) | 4 (6.1) | 6 (5.0) |
| PsA (yes), n (%) | 8 (14.8) | 12 (18.2) | 20 (16.7) |
| Total cholesterol (mg/dl) | 202.5 ± 41.7 | 197.1 ± 32.2 | 199.5 ± 36.7 |
| LDL cholesterol (mg/dl) | 108.0 ± 28.3 | 113.6 ± 26.9 | 111.1 ± 27.5 |
| HDL cholesterol (mg/dl) | 63.0 ± 15.4 | 57.7 ± 16.5 | 60.1 ± 16.2 |
| Triglycerides (mg/dl) | 159.7 ± 164.3 | 129.3 ± 67.5 | 143.0 ± 121.4 |
| Fasting glucose (mg/dl) | 94.4 ± 13.1 | 97.8 ± 19.4 | 96.3 ± 16.9 |
| Non‐fasting glucose (mg/dl) | 98.2 ± 19.6 | 100.3 ± 24.6 | 99.4 ± 22.5 |
| Mean blood pressure (mmHg) | |||
| Diastolic | 83.0 ± 13.1 | 78.7 ± 11.0 | 80.6 ± 12.1 |
| Systolic | 132.4 ± 16.2 | 129.1 ± 14.5 | 130.6 ± 15.3 |
| Type 2 diabetes, n (%) | 1 (1.6) | 0 | 1 (0.8) |
Data presented as mean ± SD unless otherwise specified.
Abbreviations: BMI, body mass index; BSA, Body Surface Area; HDL, high density lipoprotein; LDL, low density lipoprotein; PASI, Psoriasis Area and Severity Index; PGA, Physician Global Assessment; PsA, psoriatic arthritis; SD, standard deviation; TIL, tildrakizumab.